scholarly journals Rotigotine patches (Neupro) in early Parkinson’s disease

2008 ◽  
Vol 9 (2) ◽  
pp. 115-119
Author(s):  
Viola Sacchi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Term Treatment ◽  
Symptomatic Therapy ◽  
Movement Initiation ◽  
Motor Disability ◽  
Postural Reflex ◽  
Alternative Approach ◽  
Long Term Treatment

Parkinson’s disease (PD) is a neurodegenerative disorder secondary to the progressive loss of dopaminergic neurons in the substantia nigra (a portion of the midbrain responsible for movement initiation and coordination) and appearance of bradykinesia, resting tremor, rigidity and postural reflex impairment. The most common symptomatic therapy is levodopa, a dopamine precursor; however, long-term treatment leads to involuntary movements and response fluctuations which add to the complexities of later disease-management. Monotherapy with dopamine agonists may represent an alternative approach with a reduced likelihood of motor complications; these drugs, initially introduced as adjunctive therapy to levodopa, are less effective in controlling motor disability and tend to cause more sideeffects than levodopa itself.

scholarly journals Evaluating Dose- and Time-Dependent Effects of Vitamin C Treatment on a Parkinson’s Disease Fly Model

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Huynh Man Anh ◽  
Dao My Linh ◽  
Vuu My Dung ◽  
Dang Thi Phuong Thao
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Vitamin C ◽  
Neurodegenerative Disorder ◽  
Term Treatment ◽  
Time Dependent ◽  
Neuroprotective Effects ◽  
Long Term Treatment ◽  
High Doses

Parkinson’s disease (PD) is a common neurodegenerative disorder and characterized by progressive locomotive defects and loss of dopaminergic neurons (DA neuron). Currently, there is no potent therapy to cure PD, and the medications merely support to control the symptoms. It is difficult to develop an effective treatment, since the PD onset mechanism of PD is still unclear. Oxidative stress is considered as a major cause of neurodegenerative diseases, and there is increasing evidence for the association between PD and oxidative stress. Therefore, antioxidant treatment may be a promising therapy for PD. Drosophila with knockdown of dUCH, a homolog of UCH-L1 which is a PD-related gene, exhibited PD-like phenotypes including progressive locomotive impairments and DA neuron degeneration. Moreover, knockdown of dUCH led to elevated level of ROS. Thus, dUCH knockdown flies can be used as a model for screening of potential antioxidants for treating PD. Previous studies demonstrated that curcumin at 1 mM and vitamin C at 0.5 mM could improve PD-like phenotypes induced by this knockdown. With the purpose of further investigating the efficiency of vitamin C in PD treatment, we used dUCH knockdown Drosophila model to examine the dose- and time-dependent effects of vitamin C on PD-like phenotypes. The results showed that although vitamin C exerted neuroprotective effects, high doses of vitamin C and long-term treatment with this antioxidant also resulted in side effects on physiology. It is suggested that dose-dependent effects of vitamin C should be considered when used for treating PD.

Mood stability during acute stimulator challenge in Parkinson's disease patients under long-term treatment with subthalamic deep brain stimulation

2007 ◽  
Vol 22 (8) ◽  
pp. 1093-1096 ◽  
Author(s):  
Alexandre Berney ◽  
Michel Panisset ◽  
Abbas F. Sadikot ◽  
Alain Ptito ◽  
Alain Dagher ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Deep Brain

Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment

Neurology ◽  
1998 ◽  
Vol 50 (Issue 5, Supplement 5) ◽  
pp. S39-S45 ◽  
Author(s):  
C. H. Waters ◽  
M. Kurth ◽  
P. Bailey ◽  
L. M. Shulman ◽  
P. LeWitt ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Long Term Treatment

scholarly journals Dopamine Agonists in Parkinson’s Disease

1984 ◽  
Vol 11 (S1) ◽  
pp. 221-224 ◽  
Author(s):  
Donald B. Calne ◽  
Keith Burton ◽  
Jeff Beckman ◽  
W.R. Wayne Martin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptors ◽  
Dopamine Agonists ◽  
Drug Efficacy ◽  
Term Treatment ◽  
Low Doses ◽  
Active Metabolites ◽  
Endocrine Effect ◽  
Long Term Treatment

ABSTRACTDopamine agonists have yielded two important advances to our understanding of the basal ganglia – they have facilitated the subdivision of different classes of dopamine receptors, and they have established the fact that important dopaminergic effects can be achieved by activation of dopamine receptors in a manner that is unrelated to anoxal impulse traffic in dopaminergic neurons – a phenomenon similar in its diffuse, slow, characteristics to an endocrine effect.The tangible clinical benefit of dopamine agonists has been evident in patients with prominent dyskinesia or wearing off reactions. It is possible that earlier use of agonists, in low doses combined with similarly low doses of levodopa, may improve the long term treatment of Parkinson’s disease, but as yet there is no firm evidence.In the future, we can expect to see agonists with more prolonged effects, deriving from the formation of active metabolites. We can also hope to gain further insight into the correlations between the various animal models of dopaminomimetic activity, and specific aspects of drug efficacy and toxicity in parkinsonian patients. Such information should allow the design of improved pharmacotherapy.

Sign in / Sign up

Export Citation Format

Share Document